BioSpace News Archive

Sports medicine physicians at the Hospital for Special Surgery Sports Medicine Institute in New York City have developed the first set of guidelines for helping patients return to recreational activity safely after mild to moderate infection with COVID-19.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, provides updates regarding the following clinical trials:

With an eye toward expanding patient access and growing market share while using existing clinical resources, Genesis Health System has selected Bright.md’s SmartExam to power this new telehealth offering.

Verndari, Inc. Announces Publication in the Journal Vaccine of Early Data Using VaxiPatch ™ Vaccine System to Administer Flu Vaccine VaxiPatch ™ microneedle dermal patch is part of a novel vaccination system comprised of subunit antigens and adjuvants Preclinical data use of VaxiPatch™ microneedle dermal patch with proprietary vaccine showed significantly higher immune response at much smaller dose compared with an existing influenza vacci

Medical Group Management Association (MGMA) has designed this year’s Medical Practice Excellence Conference (MPEC20) to provide medical practices across the United States with critical, actionable guidance about how to navigate the significant challenges that medical practices are facing today.

Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription, today announced the appointment of Yasir Al-Wakeel, BM BCh, as the company’s Chief Financial Officer and Head of Corporate Development.

4D Molecular Therapeutics, a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-125 for X-Linked Retinitis Pigmentosa, a blinding and currently untreatable inherited retinal disease.

Theralase announced today that it has executed a Sponsored Research Agreement (“SRA”) with the University of Manitoba (“UM”) Medical Microbiology department to commence development of a coronavirus vaccine and therapy utilizing Theralase’s patented and proprietary PDCs.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced that its Australian operation – MediPharm Labs Australia Pty. Ltd.

ZYUS Life Sciences Inc. (“ZYUS”), a next-generation life sciences company leading scientific research and development in phyto-therapeutics, announced today that it has strengthened its leadership team with the appointm